| | |
Univariable
|
Multivariable*
|
|---|
|
Marker
|
Antiretrovirals
|
Mean fold change percentage difference (95% CI)
|
P value
|
Mean fold change percentage difference (95% CI)
|
P value
|
|---|
|
IL-6
|
TDF/FTC
|
Ref.
| | | |
|
ABC/3TC
|
1 (-67 to 41)
|
0.97
|
4 (-80 to 49)
|
0.90
|
|
EFV
|
Ref.
| | | |
|
ATV/r
|
-39 (-120 to 12)
|
0.16
|
-20 (-101 to 28)
|
0.48
|
|
LPV/r
|
38 (-8 to 63)
|
0.09
|
43 (-23 to 74)
|
0.15
|
|
hs-CRP
|
TDF/FTC
|
Ref.
| | | |
|
ABC/3TC
|
18 (-77 to 62)
|
0.60
|
7 (-155 to 66)
|
0.88
|
|
EFV
|
Ref.
| | | |
|
ATV/r
|
-16 (-139 to 43)
|
0.68
|
-34 (-203 to 41)
|
0.47
|
|
LPV/r
|
16 (-97 to 63)
|
0.67
|
41 (-29 to 82)
|
0.39
|
|
sCD14
|
TDF/FTC
|
Ref.
| | | |
|
ABC/3TC
|
7 (-13 to 3)
|
0.48
|
14 (-8 to 31)
|
0.18
|
|
EFV
|
Ref.
| | | |
|
ATV/r
|
-14 (-36 to 4)
|
0.13
|
-19 (-43 to 1)
|
0.06
|
|
LPV/r
|
-6 (-31 to 14)
|
0.57
|
-4 (-36 to 21)
|
0.77
|
|
IP10
|
TDF/FTC
|
Ref.
| | | |
|
ABC/3TC
|
16 (-22 to 42)
|
0.36
|
30 (-6 to 54)
|
0.09
|
|
EFV
|
Ref.
| | | |
|
ATV/r
|
-55 (-118 to -12)
|
0.01
|
-57 (-120 to -11)
|
0.011
|
|
LPV/r
|
-26 (-92 to 17)
|
0.27
|
-4 (-80 to 39)
|
0.87
|
|
MIG
|
TDF/FTC
|
Ref.
| | | |
|
ABC/3TC
|
-8 (-103 to 42)
|
0.80
|
24 (-62 to 65)
|
0.47
|
|
EFV
|
Ref.
| | | |
|
ATV/r
|
-146 (-306 to -45)
|
0.001
|
-136 (-339 to -27)
|
0.007
|
| |
LPV/r
|
-151 (-395 to -31)
|
0.006
|
-48 (-297 to 45)
|
0.44
|
- TDF, Tenofovir; FTC, Emtricitabine; ABC, Abacavir; 3TC, lamivudine; EFV, Efavirenz; ATV/r, Atazanavir/ritonavir; LPV/r, Lopinavir/ritonavir; IL6, Interleukin-6; hs-CRP, Highly-sensitive C-reactive protein; sCD14, soluble CD14; 1P10, Interferon-γ-inducible protein 10; MIG, Monokine induced by interferon-γ; CI, Confidence Interval.
- *Adjusted for age, smoking, prior AIDS, baseline CD4 cell count, baseline HIV viral load, HCV or HBV coinfection, and viral blips.
